Adjuvant Imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: A median follow-up of 44 months

Journal of Surgical Oncology

Volumn 104, Issue 7, 2011, Pages 760-764

  Jiang, Wei Zhong ^a   Guan, Guo Xian ^a   Lu, Hui Shan ^a   Yang, Ying Hong ^a   Kang, De Yong ^a   Huang, He Guang ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

adjuvant therapy; adverse events; GISTs; Imatinib; recurrence free survival

Indexed keywords

CD34 ANTIGEN; IMATINIB; PROTEIN S 100; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CASE CONTROL STUDY; COLON; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; LEUKOPENIA; LIVER; MAJOR CLINICAL STUDY; MALE; NAUSEA; PERITONEUM; PRIORITY JOURNAL; RASH; RECTUM; RELAPSE; SMALL INTESTINE; STOMACH; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; SURVIVAL ANALYSIS;

EID: 80255138368     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22010     Document Type: Article

References (23)

1. Miettinen M, Sobin LH, Lasota J,: Gastrointestinal stromal tumors of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29: 52-68. (Pubitemid 40023952)
2. Rutkowski P, Nowecki ZI, Michej W, et al.: Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 2007; 14: 2018-2027. (Pubitemid 46988258)
3. Miettinen M, Makhlouf H, Sobin LH, et al.: Gastrointestinal stromal tumors of the jejunum and ileum: A clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30: 477-489. (Pubitemid 43740149)
4. DeMatteo RP, Lewis JJ, Leung D, et al.: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58. (Pubitemid 30043939)
5. Kindblom L, Remotti H, Aldenborget F, et al.: Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-1269. (Pubitemid 28221878)
6. Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580. (Pubitemid 28067289)
7. Rubin BP, Fletcher JA, Fletcher CD,: Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors. Int J Surg Pathol 2000; 8: 5-10. (Pubitemid 30129563)
8. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480. (Pubitemid 34879334)
9. Blanke CD, Demetri GD, von Mehren M, et al.: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-625. (Pubitemid 351264357)
10. Nilsson B, Sjolund K, Kindblom LG, et al.: Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007; 96: 1656-1658. (Pubitemid 46847213)
11. Joensuu H,: Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411-1419.
12. NCCN Sarcoma Panel Members: NCCN Clinical Practice Guidelines in Oncology-Sarcoma. Fort Washington, PA: National Comprehensive Cancer Network; 2010. NCCN Publication V.2.2010.
13. Cohen MH, Cortazar P, Justice R, et al.: Approval summary: Imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. Oncologist 2010; 15: 300-307.
14. Casali PG, Blay JY,: Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21: v98-v102.
15. Dematteo RP, Ballman KV, Antonescu CR, et al.: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104.
16. DeMatteo RP, Owzar K, Antonescu CR, et al.: Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST)at high risk of recurrence: The US Intergroup phase II trial ACOSOG Z9000. [Abstract]. American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, January 25-27, 2008, Orlando, FL. A-8, 2008.
17. Eisenberg BL, Harris J, Blanke CD, et al.: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99: 42-47.
18. Armbrust T, Sobotta M, Ramadori G,: Follow up of three cases after adjuvant treatment of high risk gastrointestinal stromal tumors with Imatinib. Ann Oncol 2007; 18: 1123-1125. (Pubitemid 47050510)
19. Lee JL, Ryu MH, Chang HM, et al.: Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response. Jpn J Clin Oncol 2006; 36: 704-711.
20. Blay JY, Le Cesne A, Ray-Coquard I, et al.: Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007; 25: 1107-1113. (Pubitemid 46596763)
21. Le Cesne A, Ray-Coquard I, Bui BN, et al.: Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: An open-label multicentre randomised phase 3 trial. Lancet Oncol 2010; 11: 942-949.
22. Van Glabbeke M, Verweij J, Casali PaoloG, et al.: Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23: 5795-5804.
23. Nikfarjam M, Kimchi E, Shereef S, et al.: Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy. J Gastrointest Surg 2008; 12: 2023-2031.